Dr. Reddy's Laboratories Limited reported INR 335.9B of revenue over the trailing twelve months, +3.2% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: INR 335.9B (to FY2026). Net income: INR 42.9B, trailing twelve months to FY2026. Free cash flow: INR 33.4B, trailing twelve months to FY2026. Operating margin: 15%, trailing twelve months to FY2026.

RDYDr. Reddy's Laboratories Limited

Healthcare

$13.19-7.2% 1Y

$13.19

$11.4052 weeks$15.40

RDY as reported

Dr. Reddy's Laboratories Limited reported INR 335.9B of revenue over the trailing twelve months, +3.2% on the year before. 10 reported series are charted on this page, each one as filed.

INR 335.9B

Revenue, trailing twelve months · to FY2026 · +3.2% against the twelve months before

Net income: INR 42.9B
Net income · −24% year on year · trailing twelve months to FY2026
Free cash flow: INR 33.4B
Free cash flow · +77% year on year · trailing twelve months to FY2026
Operating margin: 15%
Operating margin · trailing twelve months to FY2026

Details›

Every series Ryufin has for RDY, trailing twelve months
Series	Latest	Year on year	As of
Revenue	INR 335.9B	+3.2%	FY2026
Net income	INR 42.9B	−24%	FY2026
EPS	INR 51.42	−24%	FY2026
Gross margin	53%	n/a	FY2026
Operating margin	15%	n/a	FY2026
Net margin	13%	n/a	FY2026
ROE	11%	n/a	FY2026
ROA	7.4%	n/a	FY2026
ROIC	9.0%	n/a	FY2026
Free cash flow	INR 33.4B	+77%	FY2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.